Isolation of Attenuated Rubella-Vaccine Virus from Human Products of Conception and Uterine Cervix

Vaheri, Antti; Vesikari, Timo; Oker-Blom, N; Seppälä, Markku; Parkman, Paul D.; Veronelli, J. A.; Robbins, Frederick C.

doi:10.1056/nejm197205182862002

Cited by 68 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was in contrast to the findings in rubella-seronegative women, whose should be to protect the developing fetus by protecting the mother. Beyond this point, scientists differed on the proper specimens were quite frequently positive for virus [23]. Thus, one would anticipate that vaccine-induced antibodies would approach.…”

Section: S141mentioning

confidence: 99%

Making Vaccination Policy: The Experience with Rubella

Parkman¹

1999

CLIN INFECT DIS

Self Cite

View full text Add to dashboard Cite

The massive rubella epidemic of 1962-1965 stimulated the development of rubella vaccine. Once vaccines were developed, the U.S. vaccination program, initially focused on infants and children, reduced both rubella and congenital rubella. However, later extension of vaccination to certain older age groups achieved significantly better control. While rubella clearly is not the perfect model for pertussis, a review of its history is illuminating. Current rubella vaccination policies resulted from an evolution in scientific understanding. Controversies, including those related to communicability, reactivity, and teratogenicity of the rubella vaccine virus, duration of immunity following vaccination, and protection following reinfection, led countries to use different approaches for national immunization programs. These differences were eventually resolved by clinical and epidemiological research coupled with rigorous scientific debate. Increased scientific understanding of pertussis, its epidemiology, and the effects of the new pertussis vaccines will similarly enable informed decision making on whether to extend pertussis immunization to adolescents and adults.

show abstract

Section: S141mentioning

confidence: 99%

Making Vaccination Policy: The Experience with Rubella

Parkman¹

1999

CLIN INFECT DIS

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is of particular importance if the vaccine is to be used during pregnancy. The recovery of rubella vaccine viruses from the extra-embryonic membranes and tissues of aborted fetuses confirms transplacental passage in viremic pregnant women and thus precludes the use of these vaccines among post-pubertal females unless cautioned regard ing pregnancy (245)(246)(247)(248)(249)(250). Further attenuation of vaccine viruses' to elimi nate the risk of viremia has been associated with decreased antigenicity (184)(185)(186).…”

Section: Viremiamentioning

confidence: 99%

“…Since all available data point to a closer similarity between the RA 27/3 rubella vaccine virus and wild rubella virus, it is entirely possible that the human cell origin (WI-38) of the RA 27/3 may increase its embryopathic potential over that of vaccines of duck embryo, rabbit kidney, or dog kidney cell origin. Existing data relate pri marily to fetuses and newborns from women inadvertently inoculated with the latter vaccines (245)(246)(247)(248)(249)(250). Long-term sequelae, even with these vaccines, have not been ruled out.…”

Section: Embryopathic Potential Of Rubella Vaccine Virusesmentioning

confidence: 99%

Immunizing Agents: Potential for Controlling or Eradicating Infectious Diseases

Wehrle¹,

Wilkins²

1981

Annu. Rev. Public Health

View full text Add to dashboard Cite

“…The attenuated rubella-vaccine virus has been shown to cross the placenta and was found in products of conception as well as in the uterine cervix [Phillips et al, 1970;Vaheri et al, 1972;Bolognese et al, 1973;Ebbin et al, 1973;Wyll and Herrmann, 1973;Fleet et al, 1974]. Serological evidence of congenital rubella infection was found in clinically normal infants born to mothers vaccinated in early pregnancy [Hayden et al, 1980].…”

Section: Introductionmentioning

confidence: 99%

Pregnancy outcome following rubella vaccination: A prospective controlled study

Bar‐Oz

Levichek

Moretti

et al. 2004

American J of Med Genetics Pt A

View full text Add to dashboard Cite

The rubella virus is a potent human teratogen. Because the rubella vaccine is prepared with live virus, a high level of anxiety surrounds exposure in pregnancy. There is relatively scarce data on fetal risk following vaccination in pregnancy, and all of the available data were collected retrospectively. Our objective was to examine whether periconceptional exposure to rubella vaccine can cause the congenital rubella syndrome, and to compare the rate of major malformations and developmental milestones among offspring of women who received rubella vaccine 3 months pre- or post-conception to an unexposed comparison group. We collected prospectively and followed up 94 women who received rubella vaccination 3 months pre- or post-conception and a comparison group that consisted of 94 women who were counseled during pregnancy in a similar manner but were not exposed to known teratogens. The controls were matched for age, smoking, alcohol, and drug use. Not any of the women exposed to the vaccine gave birth to a child with congenital rubella syndrome. Rates of major malformations were similar in both groups as were birth weights and developmental milestones. In contrast, the rate of therapeutic abortions was higher in the exposed group (7.4% vs. 0%) (P < 0.05), due to fears of teratogenicity. We conclude that rubella vaccination in pregnancy does not appear to affect pregnancy outcome in general or cause congenital rubella syndrome in particular.

show abstract

Isolation of Attenuated Rubella-Vaccine Virus from Human Products of Conception and Uterine Cervix

Cited by 68 publications

References 20 publications

Making Vaccination Policy: The Experience with Rubella

Making Vaccination Policy: The Experience with Rubella

Immunizing Agents: Potential for Controlling or Eradicating Infectious Diseases

Pregnancy outcome following rubella vaccination: A prospective controlled study

Contact Info

Product

Resources

About